Interestingly, serum levels of amylase and lipase in this patient were reduced after treatment.<h4>Conclusion</h4>We reported, for the first time, a case of metastatic HCC with asymptomatic hyperamylasemia, and suggested that HCC patients with asymptomatic hyperamylasemia may benefit from combined immunotherapy of anti-CTLA-4 and PD-1 antibodies. The gene discussed is PDCD1; the disease is hyperamylasemia.